Browse Studies — Arctuva

Phase 2

CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;…

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation

Estimated

~$10 – $7,500

Stephan Grupp MD PhDNCT04276870

Phase 1

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistam…

B-ALLDLBCLB ALL+8 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04512716

Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination

The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment f…

B-Cell ALLB-Cell Acute Lymphoblastic LeukaemiaB-Cell Lymphoblastic Leukemia+5 more

Estimated

~$10 – $750

Arkansas Children's Hospital Research InstituteNCT07422337